Diffuse large B-cell lymphoma: guideline history

Standard of care today →

3 dated versions from 2019 to 2023 listing 5 changes. Pick two versions to see what changed between them; the timeline below shows every version with the event it is anchored to.

From (exclusive)To (inclusive)

+2 added0 removed↔ 1 recategorisedacross 2 versions

Recategorised
Relapsed within 12 months or primary refractory, second line
CAR-T replaces salvage chemotherapy and autologous transplant for early relapse.
salvage chemoimmunotherapy then autologous transplant CAR-T (axicabtagene or lisocabtagene), category 1
Axicabtagene ciloleucel Lisocabtagene maraleucel ZUMA-7 TRANSFORM
Added
Untreated, IPI 2-5
Pola-R-CHP as a category 1 alternative to R-CHOP.
Polatuzumab vedotin POLARIX
Added
Relapsed or refractory, third line and beyond
CD20xCD3 bispecific antibodies (epcoritamab, glofitamab) after two or more lines, including after CAR-T.
Epcoritamab Glofitamab EPCORE NHL-1

Timeline

2019-06NCCN2017-2019 updates
Anchored to: FDA approvals of axicabtagene ciloleucel (October 2017) and tisagenlecleucel (May 2018) in the third line, and polatuzumab vedotin with bendamustine-rituximab (June 2019)
- addedRelapsed or refractory, third line and beyond: CD19 CAR-T (axicabtagene, tisagenlecleucel) after two or more lines.
- addedRelapsed or refractory, transplant-ineligible: Polatuzumab vedotin with bendamustine and rituximab.
2022-06NCCN2022 update
Anchored to: FDA approvals of axicabtagene ciloleucel (April 2022, ZUMA-7) and lisocabtagene maraleucel (June 2022, TRANSFORM) in the second line
- recategorisedRelapsed within 12 months or primary refractory, second line: CAR-T replaces salvage chemotherapy and autologous transplant for early relapse.salvage chemoimmunotherapy then autologous transplant → CAR-T (axicabtagene or lisocabtagene), category 1
2023-06NCCN2023 updates
Anchored to: FDA approvals of polatuzumab-R-CHP in the first line (April 2023, POLARIX), epcoritamab (May 2023) and glofitamab (June 2023)
- addedUntreated, IPI 2-5: Pola-R-CHP as a category 1 alternative to R-CHOP.
- addedRelapsed or refractory, third line and beyond: CD20xCD3 bispecific antibodies (epcoritamab, glofitamab) after two or more lines, including after CAR-T.

Other cancers

Acute myeloid leukaemia Bladder & urothelial cancer Cervical cancer Chronic lymphocytic leukaemia Colorectal cancer Endometrial cancer Gastric & gastro-oesophageal junction cancer Hepatocellular carcinoma HER2-positive breast cancer HR-positive / HER2-negative breast cancer Melanoma Multiple myeloma Non-small-cell lung cancer Oesophageal cancer Ovarian cancer Prostate cancer Renal cell carcinoma Triple-negative breast cancer (TNBC)

Each entry is anchored to a dated public event and links to the guideline body’s page for the disease; NCCN “Summary of changes” pages sit behind a free login and are not reproduced. Version labels say “update” where the NCCN version number has not been verified. Corrections are welcome via the repository.